Does Rallies show Form 4 insider transactions for COLL?

Yes. Rallies tracks COLL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is COLL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for COLL. It does not provide personalized investment advice.

COLL (Collegium Pharmaceutical, Inc. Common Stock) Stock Analysis - Insider Trades

Collegium Pharmaceutical, Inc. Common Stock (COLL) is a publicly traded Healthcare sector company. As of May 21, 2026, COLL trades at $34.78 with a market cap of $1.09B and a P/E ratio of 14.45. COLL moved +1.81% today. Year to date, COLL is -25.09%; over the trailing twelve months it is +14.22%. Its 52-week range spans $23.23 to $50.79. Analyst consensus is strong buy with an average price target of $53.40. Rallies surfaces COLL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading COLL stock inside the company?

Recent COLL insider activity includes Lurker Nancy sold 4.50K, BOHLIN GAREN G sold 8.70K, Dieter David sold 13.98K, Dieter David sold 6.22K, and Dreyer Scott sold 46.42K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

COLL Key Metrics

Key financial metrics for COLL
Metric	Value
Price	$34.78
Market Cap	$1.09B
P/E Ratio	14.45
EPS	$2.37
Dividend Yield	0.00%
52-Week High	$50.79
52-Week Low	$23.23
Volume	100
Avg Volume	0
Revenue (TTM)	$796.33M
Net Income	$74.95M
Gross Margin	60.68%

Recent COLL Insider Trades

Lurker Nancy sold 4.50K (~$161.86K) on May 13, 2026.
BOHLIN GAREN G sold 8.70K (~$323.49K) on May 11, 2026.
Dieter David sold 13.98K (~$488.10K) on Mar 18, 2026.
Dieter David sold 6.22K (~$228.11K) on Mar 9, 2026.
Dreyer Scott sold 46.42K (~$1.87M) on Mar 3, 2026.

Latest COLL News

Collegium Completes $650M AZSTARYS Acquisition, Boosts 2026 Revenue Guidance to $895M — May 12, 2026
Collegium Sees 9% Revenue Gain to $193.5M, 36% JORNAY PM Surge and Q2 AZSTARYS Deal — May 7, 2026
Collegium to Acquire AZSTARYS for $650M, Eyes $50M H2 2026 Sales Boost — Mar 19, 2026
Collegium Pharmaceutical Hits Record Quarterly Revenue, Boosts Guidance and Authorizes Buyback — Mar 10, 2026
Collegium to Showcase Two PainConnect Posters on Buprenorphine Nonmedical Use and Urine Testing — Mar 5, 2026

COLL Analyst Consensus

6 analysts cover COLL: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $53.40.

Common questions about COLL

Who is trading COLL stock inside the company?: Recent COLL insider activity includes Lurker Nancy sold 4.50K, BOHLIN GAREN G sold 8.70K, Dieter David sold 13.98K, Dieter David sold 6.22K, and Dreyer Scott sold 46.42K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for COLL?: Yes. Rallies tracks COLL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is COLL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for COLL. It does not provide personalized investment advice.